Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence
Terminated · NCT05860348
Conditions: Heart Failure
At a glance
- Research payments reported, 2025
- $17,527
- U.S. investigators named
- 5
- Sites paid
- 4
- Planned or actual enrollment
- 5
About the trial
- Sponsor
- CVRx, Inc.
- Tested
- Barostim™ System (device)
- Dates
- Started 2023-07-25; completion 2024-12-11
- Results posted
- Not yet
The purpose of this study is to develop valid scientific evidence of the safety and benefit of Barostim Therapy in the commercial setting in patients that are symptomatic despite having received CRT.
From ClinicalTrials.gov, last updated 2025-04-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Cvrx, Inc. reported $17,527 in research payments for this study in 2025 (15 payments).
Products named: Barostim Neo System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christopher P. Porterfield, MD FACC Cardiac Electrophysiology · Aurora, CO
- David N. Kenigsberg, MD Cardiac Electrophysiology · Fort Lauderdale, FL
- Naushad A. Shaik, MD Cardiac Electrophysiology · Kissimmee, FL
- Gourg Atteya, MD Internal Medicine · Cedar Knolls, NJ
- Ramesh Hariharan, MD, FHRS Cardiac Electrophysiology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Wcg Irb $11,050
- HCA Research Institute, LLC $3,018
- Florida Heart Rhythm Specialists $1,837
- Advanced Cardiology $1,623
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.